Spondyloarthritis & psoriatic arthritis

Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial

Rheumatology (Oxford)Published Secondary analysis of the CRESPA randomised trial

Authors' conclusion

The proposed MRI lower-extremity inflammation index demonstrated reliability, validity, and sensitivity to change in patients with early pSpA.

Study context

Population
Patients with early peripheral SpA (pSpA) starting the TNFi golimumab; MRI of pelvis and lower extremities46 with repeat MRI
Participants
56 patients
Primary endpoint
Reliability, validity and sensitivity to change of a novel semi-quantitative MRI lower-extremity inflammation index (75 sites, each 0-3)
Methodological detailspost-hoc analysis, Three readers; four lesion types: entheseal osteitis, entheseal soft-tissue inflammation, joint osteitis, joint synovitis/effusion
  • Post-hoc analysis
  • Three readers; four lesion types: entheseal osteitis, entheseal soft-tissue inflammation, joint osteitis, joint synovitis/effusion

Primary result

As reported in the abstract

MRI lower-extremity inflammation index: change, reliability and validity · after 24, 36 or 48 weeks (sustained clinical remission)
MRI index decreased
34 of 46 patients (74%)
MRI response (decrease above smallest detectable change (SDC) of 2.8)
15 (33%)
Interreader reliability, average-measure ICC, status scores
0.92 (95% CI: 0.85-0.95)
Interreader reliability, average-measure ICC, change in scores
0.89 (0.80-0.94)
Correlation with CRP, Spearman's rho
0.41 (0.23-0.56)
Correlation with swollen joint count of 6 joints
0.47 (0.27-0.63)
Correlation with tender enthesis count of 14 entheses
0.32 (0.12-0.50)
Correlation with pain score
0.28 (0.08-0.46)

Further findings

MRI response in patients with clinical involvement of MRI-assessed lower-extremity sites (subgroup)

MRI response
13 of 28 (46%)

Original publication

Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial. Rheumatology (Oxford). Published 6 October 2022. doi:10.1093/rheumatology/keac567

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.